Patients with EGFR‐mutated lung cancer responded only poorly to PD‐1/PD‐L1 blockage, and Yu et al. [120] found an association of the EGFR‐19del mutation with reduced numbers of intratumoral CD8+ T cells at early disease stages. The gene discussed is EGFR; the disease is lung carcinoma.